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Available online xxxxDiabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness among patients
with diabetes. The appearance and the severity of the symptoms correlate with the duration of diabetes and
poor blood glucose level management. Diabetic retinopathy is also categorized as a chronic low-level inﬂamma-
tory disease; the highblood glucose level promotes the accumulation of the advanced glycation end products and
leads to the stimulation of monocytes and macrophages. Examination of protein level alterations in tears using
state-of the art proteomics techniques have identiﬁed several proteins as possible biomarkers for the different
stages of the diabetic retinopathy. Some of the differentially expressed tear proteins have a role in the barrier
function of tears linking the diabetic retinopathy with another eye complication of diabetes, namely the diabetic
keratopathy resulting in impaired wound healing. Understanding the molecular events leading to the eye com-
plications caused by hyperglycemiamay help the identiﬁcation of novel biomarkers aswell as therapeutic targets
in order to improve quality of life of diabetic patients.
Biological signiﬁcance: Diabetic retinopathy (DR), the leading cause of blindness among diabetic patients can de-
velopwithout any serious symptoms therefore the early detection is crucial. Because of the increasing prevalence
there is a high need for improved screening methods able to diagnose DR as soon as possible. The non-invasive
collection and the relatively highprotein concentrationmake the tearﬂuid a good source for biomarker discovery
helping the early diagnosis. In this work we have reviewed the administration of advanced proteomics tech-
niques used in tear biomarker studies and the identiﬁed biomarkers with potential to improve the already
existing screening methods for DR detection.
© 2016 Published by Elsevier B.V.Keywords:
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Quantitative mass spectrometry1. Diabetes, diabetic retinopathy
Diabetes Mellitus (DM) has become the epidemic of the 21st centu-
ry, the current worldwide prevalence of the disease is 2–6% [1]. DM is
described as a metabolic disorder of multiple etiology, characterized
by chronic hyperglycemia with disturbances of carbohydrate, fat and
protein metabolism resulting from defects in insulin secretion, insulin
action or both [2]. Insufﬁcient insulin action arises either due to the
damage of the producing pancreatic cells (insulin deﬁciency), or be-
cause the insulin produced cannot work properly (insulin resistance),
or due to the two mechanisms together. DM is deﬁned by the World
Health Organization (WHO) as a fasting venous plasma glucose concen-
tration of equal to or greater than 7.0mmol/L or venous plasma concen-
tration of equal or greater than 11.1mmol/L, 2 h after oral intake of 75 g
glucose [3].
The main problem with DM is the occurrence of metabolic, vascular
and neurological complications [4,5]. The effects of the disease include
long–term damage, dysfunction and failure of various organs [6]. Earlybetic retinopathy: Proteomic
016), http://dx.doi.org/10.10detection and treatment of the disease can decrease the risk of develop-
ing complications. Keeping the blood sugar level close to normal can
dramatically reduce the risk of several complications.
Patients with diabetes are at high risk (approximately 90%) of devel-
oping diabetic retinopathy (DR), which is the most common complica-
tion of diabetes mellitus [7]. Diabetic retinopathy is currently the
leading cause of blindness in the economically active population in de-
veloped countries [8]. This condition is of vascular origin, and is charac-
terized by signs of retinal ischemia (microaneurysms, hemorrhages,
exudates, intraretinal microvascular abnormalities, abnormalities in
the venous caliber and neovascularization) as well as signs of increased
vascular permeability [9]. This progresses from mild non-proliferative
disease to moderate or severe non-proliferative retinopathy (NPDR),
and can ﬁnally lead to proliferative (PDR) disease [10].
2. Inﬂammation and neurodegeneration as possible causes of DR
Diabetic retinopathy is also categorized as a chronic low-level in-
ﬂammatory disease [11–13]. The appearance and the severity of the
DR is correlated with the duration of diabetes and poor blood glucose
level management [14]. The high blood glucose level promotes theapproaches to help the differential diagnosis and to understand the
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2 É. Csősz et al. / Journal of Proteomics xxx (2016) xxx–xxxaccumulation of the advanced glycation end products [11] and leads to
the stimulation of monocytes and macrophages [12]. It was shown that
the level of circulating TNFα is signiﬁcantly higher in the serum of pa-
tients having PDR than in the serum of patients having NPDR [13]. The
level of proinﬂammatory cytokines such as MCP-1, IL6, TNFα and of
MMP-9, inducible NOS, ICAM-1 was shown to be increased in the eye
of diabetic patients [15], moreover, the balance between the pro- and
anti-angiogenic cytokines is shifted leading to elevated pro-angiogenic
cytokine levels in patients with retinopathy [16].
The uncontrolled serum glucose level, the mitochondrial and extra-
cellular reactive oxygen species (ROS) are toxic to endothelial cells and
neurons, thus contribute to their death by initiating apoptosis [17,18].
The retinal neurons and vascular cells depend on insulin receptor activ-
ity, and the reduced insulin action leads to neurodegeneration. Hence,
insulin signaling appears to provide neurotrophic actions in the retina,
and retinopathy may results in part from neurotrophin deﬁciency [19].
3. Screening in the diagnosis of DR
As timely diagnosis and therapy can signiﬁcantly slow down the de-
velopment and progression of DR, screening and appropriate follow-up
of patientswith diabetes is strongly desired [7]. Screening can be carried
out by direct and indirect ophthalmoscopy or by using the increasingly
more popular photographic methods [20]. The neovascularization and
increased vascular permeability in the retina are visible and recordable
symptoms as microaneurysms and macula edema and their detection
could substantially contribute to the differential diagnosis of the DR
[21,22].
Photographic methods currently use digital images with subsequent
grading by trained individuals. Regular DR screening is centralized in
several developed countries due to cost-efﬁciency and quality control
issues [23]. More than 50% of screened patients in general, are negative
(no-DR) and are advised to be rescreened within a year [24]. All the
available DR screening methods rely on the involvement of human re-
sources which contributes greatly to the costs of these methods. In
order to improve scalability and cost-effectiveness, several research
groups are working on developing automated image analysis technolo-
gies [25]. Preliminary results are promising, sensitivity and speciﬁcity
indicators of automated systems are close to that of human graders
[26,27]. A hallmark of DR is the appearance of microaneurysms (MAs).
As these out-pouches occur on small blood vessels, most of the image
processing-based screening methods concentrate on the detection of
this type of lesions [28]. Besides computer-based image processing,
other methods can also support DR screening. Tear ﬂuid proteomics is
such a possible novel tool for population screening, which is based on
the pre-screening of a large number of patients and uses human graders
only in positive or ambiguous cases [29].
In order to increase the sensitivity and speciﬁcity values of diabetic
retinopathy screening method, our research group used a MA detector
combinedwith tearﬂuid proteomics-basedmethodologies in one single
system [30]. In case of the ﬁrst model, MA-count was used as the only
feature for detecting DR resulting in 0.84 sensitivity and 0.81 speciﬁcity
values. Using only the proteomics data for analysis 0.87 sensitivity, and
0.68 speciﬁcity values were achieved by using GBM (gradient boosting
machine) models. The combined model resulted in a more powerful
classiﬁer, achieving 0.93 sensitivity and 0.78 speciﬁcity values, as the
two different types of data provided independent and complementary
aspects of the underlying information of the outcome. The use of prote-
omics data deﬁnitely improved the performance of the computer-based
MA detector; therefore the combined screeningmethod could be a pos-
sibility to reach the human grader's sensitivity and speciﬁcity [30].
4. Proteomic methods applied for DR diagnosis
The study of proteins differentially expressed in the eyes of patients
with DR may provide biomarkers which can help the diagnosis. BothPlease cite this article as: É. Csősz, et al., Diabetic retinopathy: Proteomic
underlying molecular mechanism..., J Prot (2016), http://dx.doi.org/10.10gel-based and gel-free approaches are used to gain information on the
proteome-wide changes and to identify individual proteins which can
help to understand the pathomechanism of DR and to be used as poten-
tial biomarkers.
Two dimensional electrophoresis (2DE) is a versatile gel-based
technique making possible the qualitative and quantitative analysis
of proteins [31]. In the ﬁrst dimension the complex protein mixture
is separated based on the charge (pI) followed by a separation
based on the size in the second dimension. The gel image analysis
can visualize the spots showing differential expression between
samples/conditions and the mass spectrometry-based protein iden-
tiﬁcation can identify the proteins present in the selected spots
[32]. The combination of 2DE with protein identiﬁcation can give in-
formation about the protein level changes characteristic for different
conditions [33]. A more sophisticated form of 2DE is the differential
gel electrophoresis (DIGE) where the samples originating from dif-
ferent sample groups are labeled with ﬂuorescent dyes and are
mixed and processed together. After the implementation of 2DE
the gel is scanned with laser scanner and the differential image char-
acteristic for each ﬂuorescent dye (sample) can be visualized [34]
thus saving time and reducing the workload.
The gel-free approaches includeusually liquid chromatographic (LC)
separation of proteins preceded in many cases by other off-line separa-
tion techniques such as solid-phase extraction or strong cation ex-
change [35,36]. In typical conditions the LC is coupled on-line with
mass spectrometer and the proteins/peptides eluted from an analytical
column are directly injected into the mass spectrometer for identiﬁca-
tion and/or quantiﬁcation [37].
Quantitative proteomics is able to monitor the relative or absolute
changes of individual protein levels in various conditions. Chemical la-
beling with iTRAQ or TMT makes possible the labeling of up to 8 or 10
different sampleswith an isobaric label [38–43]. The label is constructed
in thatway that them/z values of the peptides originating fromdifferent
samples (precursor ions) are the same but during fragmentation the la-
beling group is released and the rest of the peptide can be used for MS/
MS based protein identiﬁcation. Based on the area-under the curve
(AUC) values of the labeling groups the relative amounts of the proteins
in the studied samples can be calculated [44]. One drawback of the
chemical labeling can be the insufﬁcient efﬁciency of the labeling reac-
tion and also the presence of the side-products which can make the
evaluation of the results problematic. Targeted proteomics based on se-
lected/multiple reaction monitoring (SRM/MRM) has the beneﬁt of
high sensitivity and speciﬁcity making possible the simultaneous quan-
tiﬁcation of multiple proteins [45,46]. In this setup two restrictions are
applied mainly to triple quadrupole-containing mass spectrometers. In
the ﬁrst quadrupole only the ions with the speciﬁed Q1 m/z value are
stabilized and these ions can arrive to the second quadrupole where
the fragmentation happens. In the third quadrupole the second restric-
tion is applied; fragments only with the speciﬁed Q3m/z values are sta-
bilized and can reach the detector. The AUC of the recorded peaks is
proportional with the amount of samples introduced into the mass
spectrometer. According to the gold standard stabile isotope labeled
counterparts of the studied peptides are added in known amounts to
the sample and are used both as a qualitative and quantitative reference
throughout the experiments [47]. This method does not involve any la-
beling but prior information is needed for assay design.
The otherwidely used quantiﬁcation technique is the so called label-
free quantiﬁcation. In this case the AUC of the precursor ion or the num-
ber of theMS/MS events are used for quantiﬁcation [48]. One limitation
of this method can be that it can be applied only onmass spectrometers
providing high accuracy and high scanning rate [49].
As the number of laboratories having better performing mass spec-
trometers increases, the parallel reaction monitoring (PRM) and
SWATH techniques can provide even more qualitative and quantitative
data [50–52] on proteome changes in different conditions and can pro-
vide valuable information for biomarker studies.approaches to help the differential diagnosis and to understand the
16/j.jprot.2016.06.034
3É. Csősz et al. / Journal of Proteomics xxx (2016) xxx–xxxTo ﬁnd diagnostic markers for DR the most logical material to be
studied is retina, the site of DR complications. Analysis of retinal pro-
teins can be considered as a direct way of identifying the occurrence
and development of DR. Membrane samples from PDR patients and pa-
tients with idiopathic epiretinal membranes (ERMs) were analysed
with LC-MS. A total of 225 and 154 proteins were found in the PDR
and ERM groups, respectively; 123 being present in both groups, and
102 proteins were unique to PDR and 31 to ERM groups. Periostin as a
candidate marker for PDR was chosen and the proteomics result were
conﬁrmed by RT-PCR [53]. Further research on the retina proteome
has been performed using animal models. Retinas of diabetic rats treat-
ed with grape-seed extract (GSPE) were analysed using 2-DE and mass
spectrometry-based protein identiﬁcation. A total of 18 proteins were
found to be differentially expressed in diabetic rats comparedwith nor-
mal rats. The level ofαB-crystallin,βA4-crystallin,αA-crystallin, ubiqui-
tin carboxy-terminal hydrolase L1, G protein β1, Ig-2A and pyruvate
kinase reduced to normal following treatment with GSPE [54]. The au-
thors hypothesized that the downregulated proteins might play key
roles in the development of and recovery from DR [54]. In another
study inmice, members of crystallin family were found to be upregulat-
ed, and the level of each crystallin changed during the course of diabetes
treatment [55]. Both systemic and local insulin treatments reversed the
upregulation of crystallins, therefore the authors suggested that insulin
treatment could reduce the level of apoptosis observed in DR and noted
the possible role that crystallins may play in DR. The increased expres-
sion of I-CAM [56] and VEGF was detected in the diabetic retina and
VEGF responsible for neovascularization emerged as a therapeutic tar-
get in DR treatment; intravitreal application of anti-VEGF agents are
often used [57].
Besides retina, another sample source which is subjected to exten-
sive studies is the vitreous humour which is in close proximity to the
retina and may reﬂect the retinal changes. The vitreous humour is a
transparent, gelatinous mass making up about 80% of the volume of
the eyeball and is located between the lens and the retina. It plays an
important role in providing metabolic nutrient requirements of the
lens, coordinating eye growth and providing support to the retina.
Most of the proteins being identiﬁed in vitreous humour so far, such
as albumin, transferrin, apolipoprotein, IgG, transthyretin [58,59], are
also found in serum [60]. The vitreous contains matrix metalloprotein-
ases (MMPs) [61], which are zinc-dependent enzymes maintaining
the structure and function of the extracellular matrix [62]. In a compar-
ative proteomics study the protein composition of retina and vitreous
humour was analysed showing proteins which functionally interact
with each other to control oxidative stress, immune reactions and the
exchange of intracellular proteins between the retina and vitreous
[63]. It was demonstrated that the total protein content reported for
the vitreous of patients with DR is higher than in the non-diabetic and
control samples [64].
Most proteomic studies have been conducted on vitreous ﬂuid ob-
tained from diabetic patients undergoing surgery for PDR. Vitreous hu-
mour proteins from PDR patients and non-diabetic patients with
macular holes was studied using DIGE followed by mass spectrometry.
The upregulation of zinc-α2-glycoprotein, apolipoprotein (APO) A1,
APOH, ﬁbrinogen A, complement factors C3, C4b, C9 and factor B and
downregulation of pigment epithelial-derived factor, interstitial reti-
nol-binding protein and inter-α-trypsin inhibitor heavy chain was ob-
served [65]. Other researchers also observed elevated APOA1 and
APOH levels in PDR patients which may lead to nutritional disorders
and induce disease [66].
Another widely studied sample is the aqueous humour, the ﬂuid in
the anterior and posterior chamber of the eye produced by the
pigmented and non-pigmented epithelium of the ciliary body. After se-
cretion into the posterior chamber, the aqueous circulates through the
pupil into the anterior chamber. In comparison to serum, aqueous hu-
mour has a much lower protein concentration (approximately 0.2–
0.5 mg/mL) [67] creating a challenge for proteomic studies.Please cite this article as: É. Csősz, et al., Diabetic retinopathy: Proteomic
underlying molecular mechanism..., J Prot (2016), http://dx.doi.org/10.10Nevertheless, plasma proteins like albumin, globulins [68], and transfer-
rin [69] are present in the aqueous humour [70]. A study comparing the
aqueous humour proteins between DR and control groups shown the
upregulation of APOA1, serotransferrin, keratin type I cytoskeletal 9,
keratin type I cytoskeletal 10, growth factor receptor-bound protein
10, brain-speciﬁc angiogenesis inhibitor 1-associated protein 2 and cys-
tathionineβ-synthase, and downregulation ofmatrixmetalloproteinase
13, podocan and selenoprotein P in the DR group [71].
The retina, vitreous and aqueous humours can give reliable informa-
tion regarding DR pathogenesis but they can only be collected by inva-
sivemethods duringdifferent forms of surgery carried out inmost of the
cases tomanage the complications of theDR, thus they cannot bewidely
used for diagnostic purposes. The non-invasive character of the bio-
markers is critical in case of DR diagnosis as far as screening methods
are available and are used as a gold standard in DR diagnosis. Methods
which are able to improve the screening performance are required,
preferably methods which can be carried out by general health care
practitioners.
5. Tear proteomics as a tool in DR speciﬁc biomarker studies
The necessity for other modalities which are able to improve the
sensitivity and speciﬁcity of DR diagnosis has turned researchers toward
non-invasively collected samples and led to the intensive studies on the
identiﬁcation of tear biomarkers which alone or in combination with
other methods can be used for screening purposes. The protein compo-
sition of tear ﬂuid has been investigated by numerous research groups
and more than 1500 proteins have been identiﬁed so far [72–74].
Concerning the fact that tear is not in direct contact with retina the uti-
lization of tear as a source of biomarkers in DR can be questionable. Tak-
ing into account that in DR there are problems with the alterations of
the vasculature which in turn lead to retinal changes [75] the altered
blood ﬂow can modulate the composition of the tear secreted by lacri-
mal gland and in this way the tear may reﬂect the changes of the retina
even if there is no direct contact between them. It is not known if there
is any direct, cause-effect relationship between retinal processes and
the change in the composition of the tear proteins but correlation be-
tween PDR progression and tear protein proﬁle changes were demon-
strated. Some of the proteins were identiﬁed as possible biomarkers
for diabetic retinopathy, even if they may have not directly been impli-
cated in the pathomechanism of DR. Signiﬁcantly elevated levels of
nerve growth factor, APOA1, lipocalin 1, lactotransferrin, lacritin, lyso-
zyme C, lipophilin A and immunoglobulin lambda chain have been ob-
served in PDR, while reduced level of lipocalin-1, hsp27, β2-
microglobulin and increased levels of endothelin and neuron-speciﬁc
enolase were shown in tears of patients with NPDR [38,76–79]. There
is high need for the identiﬁcation of useful biomarkers for diagnosis
and monitoring the progression of the DR, proteins which are able to
distinguish between the patients without retinopathy, with non-prolif-
erative and with proliferative stages of DR. It should be mentioned that
different sets of proteins were identiﬁed as potential biomarkers in ret-
ina, vitreous, aqueous humour and tears, the only overlap is the pres-
ence of APOA1 in vitreous, aqueous humour and tears (Table 1). The
so far identiﬁed potential biomarkers are mainly highly abundant tear
proteins which may not have direct implication in the pathogenesis of
DR; the alterations in their levels can rather be the consequence of the
disease. More studies with larger sample size are needed to validate
these potential biomarkers. There are some factors which make the
comparison of the results of biomarker studies difﬁcult: (1) the number
of the patients enrolled, (2) the groups selected for study, (3) the type of
tears used for analysis, (4) the applications of different tear collection
techniques and ﬁnally (5) the different proteomic strategies applied.
Practically there are four different possible groups to study: i) healthy,
normal controls without diabetes, ii) diabetic persons without retinop-
athy, iii) patients with non-proliferative or early stage and iv) patients
with advanced or proliferative stage of retinopathy. In different studiesapproaches to help the differential diagnosis and to understand the
16/j.jprot.2016.06.034
Table 1
Potential biomarkers for DR identiﬁed in the different parts of the eye.
Retina Vitreous Aqueous humour Tear
Periostin [53] Zinc-α2-glycoprotein [64] APOA1 [70] Nerve growth factor [74]
Crystallins [54,55] APOA1 [64,65] Serotransferrin [70] APOA1 [75]
Ubiquitin carboxy-terminal hydrolase L1
[54]
APOH [64,65] Keratin type I cytoskeletal 9 [70] Lipocalin 1 [38,76]
G protein b1 [54] Fibrinogen A [64] Keratin type I cytoskeletal 10 [70] Lactotransferrin [38]
Ig-2A [54] Complement C3 [64] Growth factor receptor-bound protein 10 [70] Lacritin [38]
Pyruvate kinase [54] Complement C4b [64] Brain-speciﬁc angiogenesis inhibitor 1-associated protein
2 [70]
Lysozyme C [38]
VEGF [56] Complement C9 [64] Cystathionine b-synthase [70] Lipophilin A [38]
Complement factor B [64] MMP-13 [70] Immunoglobulin lambda chain
[38]
Pigment epithelial-derived factor [64] Podocan [70] Hsp27 [76]
Interstitial retinol-binding protein
[64]
Selenoprotein P [70] β2-Microglobulin [76]
Inter-α trypsin inhibitor heavy chain
[64]
Enolase [77]
4 É. Csősz et al. / Journal of Proteomics xxx (2016) xxx–xxxvarious combinations of the patients groups are used. In general, the
number of patients enrolled into each group is below 20; there are
fewer studies carried out on higher number of patients [38,76]. Regard-
ing the sample type used for biomarker studies, besides tears different
biological ﬂuids such as serum [79] and vitreous [80]were utilized. Con-
sidering the tears, the different sample collection techniques applied
may introduce another level of variations. Studies carried out may in-
clude the unstimulated basal tear or the reﬂex tearwhich has an altered
composition as a response to injury or tear production stimulation such
as application of intranasal ethanol [81]. It appears that themost reliable
method would be the basal tear collection with a clean glass capillary
without disturbing the eye in any way [82]. Another widely usedmeth-
od in routine clinical applications is with Shirmer's strip which uses a
strip of absorbent paper placed into the lower eyelid provoking a low-
grade irritation practically making impossible the collection of basal
tears. Comparing the proteins identiﬁed from tears using either capil-
lary or Shirmer's strip have revealed that the number of proteins identi-
ﬁed using Shirmer's strip for tears collection is higher [83] highlighting
themore invasive feature of themethod. Also it should be noted that the
progression of diabetes is associatedwith dry eye disease,which ismore
prevalent in patients with PDR [84]. In these cases the collection of basal
tears with glass capillary can be very problematic or even impossible
[85].
Tear proteins have been studied using a wide array of protein detec-
tion methods as well as proteomics techniques from antibody-based
ELISA and Western blot to the more sophisticated mass spectrometry
methods [85]. Electrophoresis [86], protein arrays [87] and various
mass spectrometry-related techniques [85,88] have been applied. Vari-
ous forms of chemical labeling [39,43], SRM/MRM-based targeted pro-
teomics and label free quantiﬁcation have been used for tear studies
but no PRM or SWATH analyses have been carried out so far [89,90].
These more advanced quantitative proteomics techniques making
possiblemore sensitive analyses are extremely important in tear studies
because the assays with lower sensitivity usually can give information
only about the changes of the abundant tear proteins. The presence of
the highly abundant proteins can be a limitation in the tear proteome
analyses but in many cases the changes of the abundant tear proteins
can have diagnostic importance as well [91,92].
6. The chemical barrier of the tears as a possible source for
biomarkers
At those sites where our body comes in contact with potential path-
ogens, a well-deﬁned chemical barrier exists. The chemical barrier pro-
vides a passive protection against the infections by diluting the
pathogens, aswell as an active one by carrying the secreted antibacterial
and antiviral proteins that inhibit bacterial growth [93]. Regarding thePlease cite this article as: É. Csősz, et al., Diabetic retinopathy: Proteomic
underlying molecular mechanism..., J Prot (2016), http://dx.doi.org/10.10protein composition of the chemical barrier it appears that the highly
abundant proteins have protective properties. In case of sweat and
tears it was demonstrated that the proteins comprising more than 90%
of the secreted proteins have a role in defense [74,94].
In good agreement with the above-mentioned roles, the functional
analysis of the tear proteome revealed that the major tear proteins
such as lactoferrin, lysozyme C, and lipocalin, are involved in the im-
mune and inﬂammatory processes, oxidative stress response and de-
fense against pathogens [72,74,85,88]. It has been shown that
lactotransferrin is active against microbes and parasites and it has
been implicated in the protection against cancer [95]. Because of its
iron sequestration activity, lactotransferrin has an important role in
the prevention of bacterial colonization. The level of tear
lactotransferrin reﬂects the lacrimal gland function [96] which can
have diagnostic value in several pathological conditions [97,98]. Lyso-
zyme-C is a hydrolytic enzyme with muraminidase activity required
for the peptidoglycan degradation of the bacterial cell wall [95]. Besides
its antimicrobial activity, lysozyme-C has various functions including
activity against several fungi [99] and protection against HIV infection
[100]. A recent study revealed 32 protease inhibitors in tears such as
cystatins, lipocalin-1 and -2,α2-macroglobulin andα2-HS-glycoprotein
[72]. This large number of protease inhibitors indicates that the chemi-
cal barrier of the eyemay have an active defensemechanismagainstmi-
crobial proteases andmay limit the cell damage caused by the proteases
secreted into the tear ﬂuid.
Other important but low abundance components of the chemical
barrier are the proteins and peptides belonging to the antimicrobial
and immunomodulatory peptide (AMP) family being part of the innate
immune system and forming the chemical barrier in the ﬁrst line host
defense. The chemical barrier contains mostly constitutively expressed
AMPs, while some of them show inducible feature upon pathogenic or
other stimuli. The tear ﬂuid contains several prototypic AMPs such as
defensins, dermcidin and LL-37 cathelicidin [74,85,101,102]. Defensins
are small cationic peptides produced by epithelial cells with cysteine
rich sequences forming a very stable 3D structure [103]. The two sub-
families of defensins (α- and β-defensins) show broad antimicrobial
as well as antifungal and antiviral activities [95,104]. While some
defensins, like β-defensin 1 show constitutive expression pattern,
other members of this family found to be induced upon pathogenic or
inﬂammatory stimulations [105]. Using an SRM-based targeted proteo-
mics method to study the β-defensin 1, 2, 3 and 4 levels in tear it was
demonstrated that the level of β-defensin 2 was the lowest, the
level of β-defensin 3 was the highest and the levels of β-defensin 1
and β-defensin 4 were very similar to each other [106]. LL-37
cathelicidin is an α-helix type AMP of the tear ﬂuid mainly produced
by the corneal epithelial cells. Similar to the defensins, cathelicidin ex-
erts various antimicrobial [102] and immunomodulatory functionsapproaches to help the differential diagnosis and to understand the
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wound healing [107]. Dermcidin, themain skin AMPpresent in tears ex-
erts broad spectrum antimicrobial activity [108–110]. The mRNA ex-
pression of dermcidin has been detected in corneal and conjunctival
epithelial cells [111]. As far as in the chemical barrier different concen-
trations of the various host defense proteins can be observed, practically
an AMP cocktail is presentwhich implies interactions between the AMP
molecules. It has been shown that β-defensin 4 functions as a synergis-
tic partner of lysozyme-C and together with β-defensin 3 exert antimi-
crobial and immunomodulatory activities [112]. Another synergistic
partner of lysozyme-C was found to be lactotransferrin [113].
The composition of the AMP cocktail changes constantly, implying
both qualitative and quantitative changes of the cocktail components,
in order to adapt to various conditions. By analyzing someof the compo-
nents of the chemical barrier using SRM-based targeted proteomic assay
our group could demonstrate the changes of the chemical barrier com-
position related to the progression of diabetic retinopathy.
Most probably the composition of the chemical barrier is character-
istic to the stimulus to which the organism has to adapt or to the path-
ological condition causing the alteration of the chemical barrier leading
to the characteristic ocular symptoms. Thus the changes of the compo-
sition of the host defense proteins at the ocular surface as a response to
pathological conditions may provide a feasible source for biomarker
studies.
7. Ocular wound healing
The alterations of the chemical barrier in DR can have consequences
on the physiological processes mediated by the components of the
chemical barrier. It is well known that in diabetic patients a deregula-
tion of corneal repair mechanisms may be present accompanied by de-
layed wound healing, recurrent erosions and ulcers [9]. The so called
diabetic keratopathy is associated with wound healing complications
which may arise after vitreoretinal surgeries used for the management
of the proliferative diabetic retinopathy, where oedematous and cloudy
corneal epithelium, often manually removed to restore clarity, results
postoperatively in a poorly healing corneal epithelial surface [114]. Sim-
ilarly to the skin-related problems in diabetic foot the changes of the
composition of the chemical barrier of tears in the different stages of
the diabetic retinopathy may lead to improper defense resulting in re-
current infections and impaired wound healing (Fig. 1) [115].
The process of wound healing involves a complex, dynamic system
with cell-cell and cell-matrix interactions in response to injury. ThisFig. 1. Effect of hypergl
Please cite this article as: É. Csősz, et al., Diabetic retinopathy: Proteomic
underlying molecular mechanism..., J Prot (2016), http://dx.doi.org/10.10entire process has four sequential, overlapping phases: hemostasis, in-
ﬂammation, proliferation or tissue formation and remodeling as well
as scar formation.Normally, after the injury, thehemostatic cascade sys-
tem is activated and controlled by activators and inhibitors [116]. The
activated platelets play a key role in this step, they release several
chemicals (thrombin, thromboxane A2, serotonin, platelet activating
factor, etc.), cytokines (transforming growth factor [TGF-β], interleukin
[IL-1,IL-8], macrophage inﬂammatory protein [MIP-1 and -2], etc.) and
growth factors (platelet derived growth factor [PDGF], vascular endo-
thelial growth factor [VEGF], insulin-like growth factor [IGF-1], connec-
tive tissue growth factor [CTGF], etc.) to promote the clotting and the
further wound healing phases [117]. In the next step, the inﬂammatory
cells, like the neutrophils and the monocytes, are activated by the
chemo active agents and migrated to sites of tissue injury. Neutrophils
inﬁltrate the wound and clear it up from debris and as an effect of com-
plement system they enhance the opsonization of bacteria. Monocytes,
after transforming to macrophages, help contributing to tissue
debridement and phagocytosis but they also release growth factors
(PDGF, TGF-β, epidermal growth factor [EGF], ﬁbroblast growth factor
[FGF], etc.) to facilitate the migration of endothelial cells, ﬁbroblasts
and keratinocytes to the wound cavity. Another essential inﬂammatory
component is the T-lymphocytes, which also release cytokines (PDGF,
TGF-β, IL-4, interferon [IFN-γ], etc.) to stimulate ﬁbroblasts, macro-
phages and endothelial cell function [118]. During the proliferation
phase, the cytokines, growth factors and proangiogenic agents (ANG-1
and -2) released by inﬂammatory cells initiate the synthesis of extracel-
lular matrix (ECM) components (different types of collagens and gly-
cosaminoglycan) and the neovascularization or angiogenesis [119].
Finally, the remodeling and the formation of scar tissue through the
ECM stabilization take place. Blood vessels regress over time, and ﬁbro-
blasts induce crosslinking of collagen type I and elastin, which leads to a
dense scar tissue formation [120].
Defects or alterations in any phase of wound healing can contrib-
ute to the pathology of various diseases and cause delayed healing,
increased pain and risk of infections, as well as decreased quality of
life. A lot of systemic factors can inﬂuence the wound healing pro-
cess, for example, age, gender, hormonal status, stress, alcoholism,
smoking, medication use, inadequate nutrition, obesity and diabetes
[121]. Using wound healing models it was shown that the overex-
pression of cathepsin S and matrix metalloproteinase MMP-10
down-regulate protein kinase B and inhibit wound healing, while
c-Met is required; up-regulation of c-Met increases corneal wound
healing [9,122,123].ycemia on the eye.
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populations [124], and these alterations can result in reductions in an-
giogenesis and remodeling of the wound site. Strangely, in elderly indi-
viduals while the inﬂammation seems to be increased, at the same time
the macrophage function is reduced [125].
Several studies provided evidence that the deregulation of wound
healing is due to aberrant inﬂammation associated with obesity [126]
and diabetes [127]. Several research groups reported, that IL-1β, IL-6,
IL-8, IP-10, MCP-1 and TNFα were found to be increased in chronic
wounds [128] and also during retinopathy progression [129–131]. Fur-
thermore, impaired healing is associated with deregulation of collagen
turnover, including increased MMP; especially MMP-2 and MMP-7
[132,133] and decreased tissue inhibitors of metalloproteinase (TIMP)
activity deregulating the MMP-TIMP balance [134] as well as decrease
in angiogenesis, granulation tissue formation, and collagen deposition
[135].
There are some potential targets for therapeutic intervention in dia-
betic wound healing, and identifying the key steps of the inﬂammatory
process contributing to tissue destruction will help to control ocular
wound healing and its complications during diabetic retinopathy.
8. Conclusion
In the last decade, several studies focused on the biomarker and
therapeutic molecule identiﬁcation. Tear is an excellent candidate for
biomarker discoveries as far as it can be collected easily and it is all
the time accessible. The so-called “omics” disciplines (genomics, prote-
omics, metabolomics, etc.) help to understand the global platform of
molecular events in diabetic retinopathy and in wound healing. By
searching the up- and down-regulated proteins in tears can help to un-
derstand the pathophysiology of the eye complications related to hy-
perglycemia an may improve the quality of life of diabetic patients.
For this more standardized studies carried out on larger sample size
are needed. Having a better understanding on corneal wound healing
and microvasculature changes in diabetes may lead to the discovery of
better biomarkers for diagnostic and prognostic purposes and to identi-
ﬁcation of therapeutic target molecules which can be used for drug
development.
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